CR20210342A - Substituted oxopyridine derivatives - Google Patents
Substituted oxopyridine derivativesInfo
- Publication number
- CR20210342A CR20210342A CR20210342A CR20210342A CR20210342A CR 20210342 A CR20210342 A CR 20210342A CR 20210342 A CR20210342 A CR 20210342A CR 20210342 A CR20210342 A CR 20210342A CR 20210342 A CR20210342 A CR 20210342A
- Authority
- CR
- Costa Rica
- Prior art keywords
- oxopyridine derivatives
- substituted oxopyridine
- substituted
- derivatives
- thrombotic
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000009424 thromboembolic effect Effects 0.000 abstract 2
- 230000001732 thrombotic effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular vascular disorders, preferably thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018122825 | 2018-12-21 | ||
| PCT/EP2019/085983 WO2020127504A1 (en) | 2018-12-21 | 2019-12-18 | Substituted oxopyridine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20210342A true CR20210342A (en) | 2021-08-09 |
Family
ID=69143542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20210342A CR20210342A (en) | 2018-12-21 | 2019-12-18 | Substituted oxopyridine derivatives |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP3898633A1 (en) |
| JP (1) | JP2022514303A (en) |
| KR (1) | KR20210106504A (en) |
| CN (1) | CN113474348A (en) |
| AR (1) | AR117435A1 (en) |
| AU (1) | AU2019407909B2 (en) |
| BR (1) | BR112021009435A2 (en) |
| CA (1) | CA3124220A1 (en) |
| CL (1) | CL2021001613A1 (en) |
| CO (1) | CO2021007908A2 (en) |
| CR (1) | CR20210342A (en) |
| DO (1) | DOP2021000128A (en) |
| EA (1) | EA202191764A1 (en) |
| EC (1) | ECSP21043895A (en) |
| IL (1) | IL283990A (en) |
| JO (1) | JOP20210161A1 (en) |
| MA (1) | MA54521A (en) |
| MX (1) | MX2021007508A (en) |
| PE (1) | PE20211790A1 (en) |
| SG (1) | SG11202104384PA (en) |
| TW (1) | TW202039510A (en) |
| WO (1) | WO2020127504A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102807521B1 (en) * | 2018-03-15 | 2025-05-16 | 바이엘 악티엔게젤샤프트 | Method for preparing two kinds of 4-{[(2S)-2-{4-[5-chloro-2-(1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl]amino}-2-fluorobenzamide derivatives |
| CN114105881B (en) | 2020-08-31 | 2024-01-26 | 沈阳海诺威医药科技有限公司 | Platelet aggregation inhibitor, and preparation method and application thereof |
| GEAP202316370A (en) | 2021-03-09 | 2023-11-27 | Bayer Ag | Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3] triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide |
| WO2022189280A1 (en) | 2021-03-09 | 2022-09-15 | Bayer Aktiengesellschaft | Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide |
| MX2023010614A (en) | 2021-03-09 | 2023-09-19 | Bayer Ag | Crystalline f. |
| CN114560754A (en) * | 2022-02-25 | 2022-05-31 | 滁州学院 | Preparation method of alkyl alcohol |
| EP4716732A1 (en) * | 2023-04-28 | 2026-04-01 | Basf Se | Use of alkyl 4-alkoxypentanoates as aroma chemicals |
| CN116874469B (en) * | 2023-09-06 | 2023-11-10 | 成都施贝康生物医药科技有限公司 | Oxo-pyridine compound, intermediate, preparation method and application thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| DE102006032824A1 (en) * | 2006-07-14 | 2008-01-17 | Bayer Healthcare Ag | Substituted indazoles |
| JP5419706B2 (en) | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | Glucokinase activator |
| US9809545B2 (en) | 2013-03-27 | 2017-11-07 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| TWI633089B (en) * | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | Substituted oxopyridine derivatives |
| US9475809B2 (en) | 2013-07-23 | 2016-10-25 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives and use thereof as factor xia/plasma |
| WO2015063093A1 (en) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
| WO2016046166A1 (en) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
| WO2016046158A1 (en) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
| JP6517925B2 (en) | 2014-09-24 | 2019-05-22 | バイエル ファーマ アクチエンゲゼルシャフト | Substituted oxopyridine derivatives |
| WO2016046156A1 (en) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
| ES2716417T3 (en) | 2014-09-24 | 2019-06-12 | Bayer Pharma AG | Derivatives of oxopyridine substituted with anti-inflammatory and antithrombotic action |
| ES2712886T3 (en) * | 2014-09-24 | 2019-05-16 | Bayer Pharma AG | Derivatives of pyridobenzazepine and pyridobenzazocine that inhibit factor XIa |
| CA2979937A1 (en) | 2015-03-19 | 2016-09-22 | Bayer Pharma Aktiengesellschaft | Oxo-pyridine-derivatives as factor xia inhibitors for the treatment of thrombosis |
| JO3703B1 (en) | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | Substituted oxopyridine derivatives |
| EP3344618A1 (en) | 2015-09-04 | 2018-07-11 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
-
2019
- 2019-12-18 EA EA202191764A patent/EA202191764A1/en unknown
- 2019-12-18 KR KR1020217022510A patent/KR20210106504A/en not_active Ceased
- 2019-12-18 SG SG11202104384PA patent/SG11202104384PA/en unknown
- 2019-12-18 CR CR20210342A patent/CR20210342A/en unknown
- 2019-12-18 BR BR112021009435-0A patent/BR112021009435A2/en not_active Application Discontinuation
- 2019-12-18 JP JP2021535063A patent/JP2022514303A/en active Pending
- 2019-12-18 MX MX2021007508A patent/MX2021007508A/en unknown
- 2019-12-18 WO PCT/EP2019/085983 patent/WO2020127504A1/en not_active Ceased
- 2019-12-18 PE PE2021000903A patent/PE20211790A1/en unknown
- 2019-12-18 EP EP19832641.5A patent/EP3898633A1/en not_active Withdrawn
- 2019-12-18 AR ARP190103745A patent/AR117435A1/en unknown
- 2019-12-18 CA CA3124220A patent/CA3124220A1/en active Pending
- 2019-12-18 CN CN201980091518.1A patent/CN113474348A/en active Pending
- 2019-12-18 TW TW108146372A patent/TW202039510A/en unknown
- 2019-12-18 MA MA054521A patent/MA54521A/en unknown
- 2019-12-18 JO JOP/2021/0161A patent/JOP20210161A1/en unknown
- 2019-12-18 AU AU2019407909A patent/AU2019407909B2/en not_active Ceased
-
2021
- 2021-06-14 IL IL283990A patent/IL283990A/en unknown
- 2021-06-16 CO CONC2021/0007908A patent/CO2021007908A2/en unknown
- 2021-06-16 EC ECSENADI202143895A patent/ECSP21043895A/en unknown
- 2021-06-17 CL CL2021001613A patent/CL2021001613A1/en unknown
- 2021-06-18 DO DO2021000128A patent/DOP2021000128A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA54521A (en) | 2022-03-30 |
| KR20210106504A (en) | 2021-08-30 |
| JP2022514303A (en) | 2022-02-10 |
| CO2021007908A2 (en) | 2021-07-19 |
| BR112021009435A2 (en) | 2021-08-17 |
| CN113474348A (en) | 2021-10-01 |
| PE20211790A1 (en) | 2021-09-09 |
| MX2021007508A (en) | 2021-08-05 |
| AR117435A1 (en) | 2021-08-04 |
| EP3898633A1 (en) | 2021-10-27 |
| DOP2021000128A (en) | 2021-09-30 |
| SG11202104384PA (en) | 2021-05-28 |
| CL2021001613A1 (en) | 2021-12-03 |
| AU2019407909B2 (en) | 2023-05-25 |
| AU2019407909A1 (en) | 2021-05-27 |
| CA3124220A1 (en) | 2020-06-25 |
| JOP20210161A1 (en) | 2023-01-30 |
| TW202039510A (en) | 2020-11-01 |
| ECSP21043895A (en) | 2021-07-30 |
| EA202191764A1 (en) | 2021-10-22 |
| WO2020127504A1 (en) | 2020-06-25 |
| IL283990A (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20210161A1 (en) | Substituted oxopyridine derivatives | |
| PH12018500057A1 (en) | Substituted oxopyridine derivatives | |
| PH12020551973A1 (en) | Substituted dihydropyrazolo pyrazine carboxamide derivatives | |
| TN2015000434A1 (en) | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | |
| ZA202402553B (en) | Substituted s-alaninate derivatives | |
| MX2016000258A (en) | Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof. | |
| PH12016502015A1 (en) | Anti-factor d antibody variants and uses thereof | |
| PH12021550872A1 (en) | Therapeutic compounds | |
| WO2018042438A3 (en) | Human blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders | |
| WO2016046156A8 (en) | Substituted oxopyridine derivatives | |
| PH12019502315A1 (en) | Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | |
| EP4364805A3 (en) | Novel pyridazines | |
| TN2016000107A1 (en) | Substituted phenylalanine derivatives | |
| WO2015106215A3 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| PH12019500535A1 (en) | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | |
| PH12021550903A1 (en) | Novel pyridazines | |
| WO2015165933A3 (en) | Imidazo[1,2-a]pyridines as soluble guanylate cyclase stimulators for the treatment of cardiovascular diseases | |
| PH12019502314A1 (en) | Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof | |
| TN2015000523A1 (en) | Substituted benzoxazoles | |
| HK1230969A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same |